Compare
ResMed Inc vs Dexcom Inc vs MiniMed Group, Inc. vs West Pharmaceutical Services Inc
| Latest fiscal year | ResMed Inc RMD | Dexcom Inc DXCM | MiniMed Group, Inc. MMED | West Pharmaceutical Services Inc WST |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2026-04-24 | 2025-12-31 |
| Revenue | $5.65B | $4.66B | $3.10B | $3.07B |
| Revenue growth (YoY) | +9.9% | +15.6% | +14.3% | +6.3% |
| Gross margin | 61.1% | 60.1% | 54.2% | 35.9% |
| Operating margin | 33.4% | 19.6% | -6.1% | 19.0% |
| Net margin | 26.9% | 17.9% | -10.7% | 16.1% |
| Net income | $1.52B | $836.30M | -$333.00M | $493.70M |
| EPS (Diluted) | $10.43 | $2.09 | -$1.30 | $6.79 |
| Operating cash flow | $1.81B | $1.44B | -$197.00M | $754.80M |
| Free cash flow | $1.65B | $1.08B | -$420.00M | $468.90M |
| Cash & equivalents | $1.47B | $917.70M | $298.00M | $791.30M |
| Total assets | $8.97B | $6.34B | $4.63B | $4.27B |
| Total liabilities | $2.38B | $3.59B | $1.02B | $1.09B |
| Shareholders' equity | $6.59B | $2.75B | $3.61B | $3.18B |
| Return on year-end equity | 23.1% | 30.5% | -9.2% | 15.5% |
| Shares outstanding | 144.24M | 384.80M | 280.82M | 72.00M |
Revenue, most recent five fiscal years
| Fiscal year | ResMed Inc | Dexcom Inc | MiniMed Group, Inc. | West Pharmaceutical Services Inc |
|---|---|---|---|---|
| Latest | $5.65B Ended 2026-06-30 | $4.66B Ended 2025-12-31 | $3.10B Ended 2026-04-24 | $3.07B Ended 2025-12-31 |
| 1 year earlier | $5.15B Ended 2025-06-30 | $4.03B Ended 2024-12-31 | $2.71B Ended 2025-04-25 | $2.89B Ended 2024-12-31 |
| 2 years earlier | $4.69B Ended 2024-06-30 | $3.62B Ended 2023-12-31 | $2.47B Ended 2024-04-26 | $2.95B Ended 2023-12-31 |
| 3 years earlier | $4.22B Ended 2023-06-30 | $2.91B Ended 2022-12-31 | n/a | $2.89B Ended 2022-12-31 |
| 4 years earlier | $3.58B Ended 2022-06-30 | $2.45B Ended 2021-12-31 | n/a | $2.83B Ended 2021-12-31 |